Structure Therapeutics (NASDAQ:GPCR) Issues Earnings Results

Structure Therapeutics (NASDAQ:GPCR) issued its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01, Zacks reports.

Structure Therapeutics Stock Up 4.1 %

NASDAQ:GPCR opened at $23.75 on Friday. The stock’s fifty day simple moving average is $26.58 and its 200-day simple moving average is $33.59. The firm has a market capitalization of $1.36 billion, a P/E ratio of -32.09 and a beta of -2.75. Structure Therapeutics has a 12-month low of $19.61 and a 12-month high of $62.74.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. JMP Securities reiterated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, William Blair assumed coverage on shares of Structure Therapeutics in a research report on Friday. They issued an “outperform” rating for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Buy” and a consensus price target of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.